Aude I Segaliny

Title: Aude I Segaliny: Innovator in Tumor Microenvironment Research

Introduction

Aude I Segaliny is a notable inventor based in Laguna Hills, CA (US). He has made significant contributions to the field of biomedical research, particularly in the development of innovative constructs for cancer treatment. His work focuses on enhancing the efficacy of immunotherapies through novel approaches.

Latest Patents

Aude I Segaliny holds a patent for "Anti-CD3 constructs and uses thereof." This patent describes tumor microenvironment acidity activated anti-CD3 constructs that bind to CD3, including anti-CD3 monoclonal and multispecific antibodies. The patent also covers nucleic acid molecules encoding an amino acid sequence of the anti-CD3, vectors comprising these nucleic acid molecules, and host cells containing the vectors. Additionally, it outlines methods for preparing the anti-CD3 construct, pharmaceutical compositions containing the construct, and methods for using the anti-CD3 construct or compositions. He has 1 patent to his name.

Career Highlights

Aude is associated with Amberstone Biosciences, Inc., where he continues to push the boundaries of cancer research. His innovative work has the potential to significantly impact the treatment landscape for patients suffering from various forms of cancer.

Collaborations

Aude collaborates with talented individuals in his field, including Yonglei Shang and Xiaoya Ma. Their combined expertise fosters a productive environment for groundbreaking research and development.

Conclusion

Aude I Segaliny is a pioneering inventor whose work in anti-CD3 constructs is paving the way for advancements in cancer immunotherapy. His contributions are vital to the ongoing fight against cancer, and his innovative spirit continues to inspire others in the field.